دورية أكاديمية
أعرض في EDS

Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

التفاصيل البيبلوغرافية
العنوان: Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
المؤلفون: Zhang, Feiyu, Ferrero, Macarena, Dong, Ning, D Auria, Giuseppe, Reyes-Prieto, Mariana, Herreros-Pomares, Alejandro, Calabuig-Fariñas, Silvia, Durendez, Elena, Aparisi, Francisco, Blasco, Ana, García, Clara, Camps, Carlos, Jantus-Lewintre, Eloisa, Sirera Pérez, Rafael
المساهمون: Universitat Politècnica de València. Escuela Técnica Superior de Ingenieros Industriales - Escola Tècnica Superior d'Enginyers Industrials, Universitat Politècnica de València. Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural - Escola Tècnica Superior d'Enginyeria Agronòmica i del Medi Natural, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad
بيانات النشر: MDPI AG
سنة النشر: 2021
المجموعة: Universitat Politécnica de Valencia: RiuNet / Politechnical University of Valencia
مصطلحات موضوعية: Gut microbiota, Biomarker, Non-small cell lung cancer, Immune checkpoint blockade, Immunotherapy, Next-generation sequencing, BIOLOGIA CELULAR
الوصف: [EN] Background: The human gut harbors around 10(13)-10(14) microorganisms, collectively referred to as gut microbiota. Recent studies have found that the gut microbiota may have an impact on the interaction between immune regulation and anti-cancer immunotherapies. Methods: In order to characterize the diversity and composition of commensal microbiota and its relationship with response to immune checkpoint blockade (ICB), 16S ribosomal DNA (rDNA) sequencing was performed on 69 stool samples from advanced non-small cell lung cancer (NSCLC) patients prior to treatment with ICB. Results: The use of antibiotics and ICB-related skin toxicity were significantly associated with reduced gut microbiota diversity. However, antibiotics (ATB) usage was not related to low ICB efficacy. Phascolarctobacterium was enriched in patients with clinical benefit and correlated with prolonged progression-free survival, whereas Dialister was more represented in patients with progressive disease, and its higher relative abundance was associated with reduced progression-free survival and overall survival, with independent prognostic value in multivariate analysis. Conclusions: Our results corroborate the relation between the baseline gut microbiota composition and ICB clinical outcomes in advanced NSCLC patients, and provide novel potential predictive and prognostic biomarkers for immunotherapy in NSCLC. ; This research was funded by grant no. CB16/12/00350 from the Centro de Investigacion Biomedica en Red de Cancer (CIBEROnc) and grant no. PI18/00266 from the Instituto de Salud Carlos III (ISCIII). ; Zhang, F.; Ferrero, M.; Dong, N.; D Auria, G.; Reyes-Prieto, M.; Herreros-Pomares, A.; Calabuig-Fariñas, S. (2021). Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. Cancers. 13(11). https://doi.org/10.3390/cancers13112514Test ; 13 ; 11
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 2072-6694
العلاقة: Cancers; info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI18%2F00266/ES/INMUNOGRAMA NO INVASIVO. APROXIMACION MULTIDIMENSIONAL PARA CARACTERIZAR Y MONITORIZAR EL ESTATUS INMUNE EN CANCER DE PULMON./; info:eu-repo/grantAgreement/MINECO//CB16%2F12%2F00350/ES/CANCER/; https://doi.org/10.3390/cancers13112514Test; http://hdl.handle.net/10251/203772Test; urn:eissn:2072-6694; PMC8196639
DOI: 10.3390/cancers13112514
الإتاحة: https://doi.org/10.3390/cancers13112514Test
http://hdl.handle.net/10251/203772Test
حقوق: http://creativecommons.org/licenses/by/4.0Test/ ; info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.924AD4A0
قاعدة البيانات: BASE
الوصف
تدمد:20726694
DOI:10.3390/cancers13112514